Found 6 matching trials
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck PHASE2 The purpose of this study is to determine if EMD 1201081 in combination wit...
Show More Location
University of Colorado Cancer Center
Learn More & Join Trial
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck PHASE1 The primary purpose of this trial is to assess the safety and tolerability ...
Show More Location
Clinical Research Unit and Pharmacology Lab EA 3035 Institut Claudius Regaud
Learn More & Join Trial
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC PHASE1 To evaluate the safety of the proposed Phase II dosage of the investigation...
Show More Location
Cancer Centers of Florida
Learn More & Join Trial
REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study PHASE3 The primary objective is to compare \& evaluate between the treatment group...
Show More Location
Clinical Site TBA
Learn More & Join Trial
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma PHASE2 * Multi-Center
* Randomized
* Open-Label Study of single agent IMO-2055
* P...
Show More Location
Georgetown University, Lombardi Cancer Center
Learn More & Join Trial
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer PHASE1 Open-label phase 1b trial. Study treatment will be administered in 3 week c...
Show More Location
Georgetown University Lombardi Cancer Center
Learn More & Join Trial